Back

In silico engineered multitarget-directed ligands for the polypharmaceutical treatment of PTEN loss of function endometrial adenocarcinoma

Delara, R.; Mujumdar, V.; Zhang, Q.; Dryden, H.; Crane, E.; Brown, J.; Naumann, W.; Puechl, A.; Foureau, D.; Sha, W.; LeGrand, J.; Yang, H.-T.; Dykema, K.; Yada, B.; McHale, C. C.; Maddeboina, K.; Pal, D.; Durden, D. L.

2026-08-31 cancer biology
10.64898/2026.08.28.747865 bioRxiv
Show abstract

To combat refractory diseases, such as cancer, multitarget-directed ligands (MTDLs) have become an emerging area of research to exploit synthetic lethality (SL) relationships associated with drug resistance. Herein, we present the in silico design of MTDLs for the polypharmaceutical treatment of endometrial adenocarcinoma (EAC) and our discovery of a novel SL in EAC; PTEN loss of function (LOF) and the inhibition of CDK9. We used high-resolution x-ray crystallographic data to chemically engineer, LCI133, to inhibit CDK9, CDK4/6-and AURKA/B kinases. PTEN LOF in EAC results in augmented deregulated transcription and a massive increase in nascent RNA, a phenotype which encodes a high level of apoptotic sensitivity to LCI133 and CDK9 inhibitors. Treatment with LCI133 results in a rapid decline nose-dive in global nRNA, MYC nRNA levels and TS elongation (TE) in PTEN LOF EAC. PTEN LOF is necessary and sufficient to confer sensitivity of EAC cells to LCI133 and other CDK9 inhibitors.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.